Sunho Biologics Past Earnings Performance
Past criteria checks 0/6
Sunho Biologics's earnings have been declining at an average annual rate of -155.3%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 847.8% per year.
Key information
-155.3%
Earnings growth rate
-150.1%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 847.8% |
| Return on equity | n/a |
| Net Margin | -756.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Sunho Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 18 | -133 | 41 | 43 |
| 30 Sep 23 | 16 | -94 | 39 | 49 |
| 31 Dec 22 | 2 | -52 | 6 | 53 |
| 31 Dec 21 | 3 | -71 | 6 | 64 |
Quality Earnings: 2898 is currently unprofitable.
Growing Profit Margin: 2898 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2898's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2898's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2898 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2898's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.